1. Home
  2. TGTX vs COMP Comparison

TGTX vs COMP Comparison

Compare TGTX & COMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$55.33

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Logo Compass Inc.

COMP

Compass Inc.

HOLD

Current Price

$12.56

Market Cap

8.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGTX
COMP
Founded
1993
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
8.8B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
TGTX
COMP
Price
$55.33
$12.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$49.80
$11.80
AVG Volume (30 Days)
2.5M
14.8M
Earning Date
05-04-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
1746.67
67.74
EPS
0.12
0.03
Revenue
$2,785,000.00
$6,961,600,000.00
Revenue This Year
$49.08
$90.43
Revenue Next Year
$26.69
$8.63
P/E Ratio
$459.33
$388.33
Revenue Growth
N/A
23.67
52 Week Low
$25.37
$6.37
52 Week High
$59.30
$13.96

Technical Indicators

Market Signals
Indicator
TGTX
COMP
Relative Strength Index (RSI) 60.43 66.24
Support Level $28.57 $7.06
Resistance Level $57.38 $13.45
Average True Range (ATR) 2.40 0.66
MACD -0.54 -0.06
Stochastic Oscillator 51.47 75.20

Price Performance

Historical Comparison
TGTX
COMP

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About COMP Compass Inc.

Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.

Share on Social Networks: